NCT07227831招募中不适用
A Phase 2 Study of TheraBionic P1 Device for Patients With Metastatic Hormone Positive Breast Cancer Post Endocrine Therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 82
- 主要终点
- Progression Free Survival (PFS)
研究概览
简要总结
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are:
- will the TheraBionic P1 device affect progression free and overall survival in advanced or metastatic HR positive, HER2 negative breast cancer
- the long term safety and tolerability of the TheraBionic P1 device
- assessment of how the disease responded to the TheraBionic P1 device
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant must have locally advanced/unresectable or metastatic Hormone Receptor (HR) positive, Human Epidermal growth factor receptor 2 (HER2) negative breast cancer as defined by the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (estrogen receptor [ER] and/or progesterone receptor [PR] >1% and HER2 negative by immunohistochemistry [IHC] and/or fluorescent in situ hybridization [FISH]).
- •Participant must have received and progressed on or are intolerant to all therapies known to confer overall survival benefit, including at least one line of endocrine + CDK4/6 inhibitor therapy AND one line of cytotoxic such as chemotherapy and/or antibody drug conjugates (ADCs).
- •Participant must be a woman ≥ 22 years old and must be able to understand and sign an informed consent form.
- •Participant must have a life expectancy of at least 3 months.
- •Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-
- •it is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of childbearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session.
- •Participants must meet one of the following:
- •Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy)
- •Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation.
- •Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence methods such as calendar, ovulation, symptothermal, or post ovulation tracking are not acceptable.
- •Not in a sexual relationship in which they may become pregnant (i.e. same-sex relationship)
- •If they are of childbearing potential, agree to use at least one method of contraception. Withdrawal is not an acceptable contraceptive method.
排除标准
- •Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
- •Participants that are taking any other investigational drugs.
- •Participants that are pregnant or breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued.
- •Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae).
- •Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid/vitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study.
- •Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device.
- •Participants with a known severe (e.g., anaphylactic) allergy to nickel
结局指标
主要结局
Progression Free Survival (PFS)
时间窗: From start of treatment to 5 years after treatment discontinuation or death, whichever comes first
PFS is defined as the time duration in days from treatment start to progression per physician discretion or death from any cause. Progression will be assessed every 2-3 months for 5 years
次要结局
- Tolerability of the TheraBionic P1 device(From first device use through end of treatment (up to 12 months))
- Overall Survival (OS)(From start of treatment to 5 years after treatment discontinuation or death, whichever comes first)
- Overall Response Rate (ORR)(From start of treatment to 5 years after treatment initiation or death, whichever comes first)
- Disease control rate (DCR)(From start of treatment to 5 years after treatment initiation or death, whichever comes first)
- Duration of response (DOR)(From start of treatment to 5 years after treatment initiation or death, whichever comes first)
- Time to progression (TTP)(From start of treatment to 5 years after treatment initiation or death, whichever comes first)
研究者
Hadeel Assad
Principal Investigator
Barbara Ann Karmanos Cancer Institute
相似试验
招募中
不适用
TheraBionic P1 Device in Subjects With Advanced Hepatocellular CarcinomaNCT07118202Barbara Ann Karmanos Cancer Institute198
已完成
1 期
Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular CarcinomaAdvanced Hepatocellular CarcinomaNCT00534664University of Sao Paulo40
已完成
1 期
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaNegative Symptoms in SchizophreniaNCT06107803Minerva Neurosciences17
招募中
2 期
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsHead and Neck Squamous Cell CarcinomaNCT06437522Sichuan Baili Pharmaceutical Co., Ltd.46
招募中
2 期
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung CancerExtensive-stage Small-cell Lung CancerNCT06437509Sichuan Baili Pharmaceutical Co., Ltd.66